NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/26/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization82.83 mln
Float0.29 mln
Earnings Date08/28/2026
1-Year Forecast
13.25
Transformational upside
Relative Strength
27
/ 100
Underperforming
Debt / Equity
0.00
Debt-free
ROE
-47.03
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Alterity Therapeutics Limited is an Australian medical research company focused on developing treatments for serious brain diseases such as Parkinson's disease and Multiple System Atrophy. Its lead treatment, ATH434, is currently being tested in multiple Phase II clinical trials targeting both conditions. The company also runs a drug discovery program that creates new chemical compounds aimed at addressing the root causes of neurological diseases. Founded in 1997 and headquartered in Melbourne, it was previously known as Prana Biotechnology Limited before adopting its current name in 2019.
